Creative Planning Sells 3,356 Shares of Xencor, Inc. (NASDAQ:XNCR)

Creative Planning cut its stake in shares of Xencor, Inc. (NASDAQ:XNCR) by 17.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,355 shares of the biopharmaceutical company’s stock after selling 3,356 shares during the quarter. Creative Planning’s holdings in Xencor were worth $291,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. GAMMA Investing LLC raised its holdings in shares of Xencor by 153.7% during the first quarter. GAMMA Investing LLC now owns 2,172 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 1,316 shares during the period. SG Americas Securities LLC acquired a new position in Xencor during the 2nd quarter worth approximately $154,000. XTX Topco Ltd bought a new position in Xencor in the second quarter worth approximately $196,000. Acadian Asset Management LLC bought a new position in Xencor in the first quarter worth approximately $206,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Xencor in the second quarter valued at approximately $212,000.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on XNCR. Wedbush reaffirmed an “outperform” rating and set a $34.00 target price on shares of Xencor in a research report on Monday, September 9th. JPMorgan Chase & Co. lowered their price objective on shares of Xencor from $30.00 to $27.00 and set an “overweight” rating on the stock in a report on Wednesday, July 31st. BMO Capital Markets reiterated an “outperform” rating and set a $32.00 price objective on shares of Xencor in a report on Tuesday, August 6th. Finally, Royal Bank of Canada upped their target price on shares of Xencor from $31.00 to $34.00 and gave the stock an “outperform” rating in a report on Thursday, September 26th. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.78.

Xencor Stock Performance

Shares of XNCR stock opened at $21.78 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.92 and a quick ratio of 6.92. The firm has a 50-day moving average of $18.99 and a 200-day moving average of $20.12. Xencor, Inc. has a one year low of $15.31 and a one year high of $26.84. The company has a market cap of $1.34 billion, a P/E ratio of -9.95 and a beta of 0.67.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.25). Xencor had a negative net margin of 132.74% and a negative return on equity of 28.23%. The firm had revenue of $16.96 million during the quarter, compared to analysts’ expectations of $21.13 million. During the same quarter last year, the business posted ($0.37) EPS. The company’s quarterly revenue was down 62.7% on a year-over-year basis. Equities research analysts forecast that Xencor, Inc. will post -4.13 EPS for the current fiscal year.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.